The RTS,S vaccine candidate for malaria

Jason A. Regules, James F. Cummings, Christian F. Ockenhouse

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been demonstrated to be safe, well tolerated, immunogenic, and to confer partial efficacy in both malaria-naive and -experienced adults as well as children. Further research to optimize and improve vaccine efficacy is ongoing.

Original languageEnglish
Pages (from-to)589-599
Number of pages11
JournalExpert Review of Vaccines
Issue number5
StatePublished - May 2011
Externally publishedYes


  • RTS,S
  • adjuvant
  • falciparum
  • malaria
  • malaria vaccine
  • prime-boost


Dive into the research topics of 'The RTS,S vaccine candidate for malaria'. Together they form a unique fingerprint.

Cite this